Tyrosinemia is a rare autosomal recessive metabolic disorder. It results from a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). This enzymatic lack causes toxic metabolites to accumulate, which subsequently damages the liver and kidneys. Early identification is vital for better clinical outcomes. Consequently, researchers are investigating long non-coding RNAs as potential Tyrosinemia diagnostic biomarkers.

A recent cross-sectional study evaluated the serum expression of NEAT1 and MALAT1 in children. The study compared 11 pediatric patients with tyrosinemia to 26 healthy controls. Specifically, the researchers used quantitative real-time PCR to measure RNA levels accurately.

NEAT1 as one of the effective Tyrosinemia diagnostic biomarkers

The results showed significant upregulation of NEAT1 in the tyrosinemia group compared to healthy individuals. Furthermore, NEAT1 displayed exceptional diagnostic accuracy. The area under the curve (AUC) reached 0.945. At a cut-off value of 1.126, it provided 100% sensitivity and 80% specificity. In contrast, MALAT1 did not show significant diagnostic utility for this metabolic condition.

Clinical correlations also highlighted the clinical importance of NEAT1. Its expression levels correlated positively with aspartate aminotransferase (AST) and alkaline phosphatase (ALP) levels. Moreover, higher MALAT1 levels showed an inverse relationship with the International Normalized Ratio (INR). These findings suggest that lncRNAs may reflect the extent of metabolic dysfunction and liver injury in affected children.

In conclusion, NEAT1 serves as a promising, non-invasive tool for clinicians. It could complement existing screening methods, especially in regions where universal newborn screening is limited. However, further validation in larger patient cohorts remains necessary to confirm these results.

Frequently Asked Questions

How does NEAT1 compare to MALAT1 as a biomarker for tyrosinemia?

NEAT1 demonstrated significantly higher expression in tyrosinemia patients and high diagnostic accuracy (AUC 0.945). Conversely, MALAT1 showed only a non-significant trend and poor diagnostic performance.

What are the sensitivity and specificity values for NEAT1 in this study?

At an optimal cut-off value of 1.126, NEAT1 achieved 100% sensitivity and 80% specificity for identifying tyrosinemia in children.

Why is finding new biomarkers important for tyrosinemia management?

Tyrosinemia causes progressive and permanent liver and kidney damage. Non-invasive biomarkers like NEAT1 allow for early diagnosis and monitoring, which is crucial for starting life-saving treatments like nitisinone.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Motazedian N et al. Evaluation of serum NEAT1 and MALAT1 expression as diagnostic biomarkers in tyrosinemia, a rare metabolic disorder. Orphanet J Rare Dis. 2026 Feb 25. doi: 10.1186/s13023-026-04275-9. PMID: 41736130.

2. Shah I. Tyrosinemia: a report of three cases from India. Indian J Gastroenterol. 2013 Mar;32(2):123-6.

3. Kuypers AM, et al. Evaluation of Neonatal Screening Programs for Tyrosinemia Type 1 Worldwide. Int J Neonatal Screen. 2024;10(4):82.